Financial News

Gilead 4Q Revenues up 26%

Revenue growth for the quarter and full year was primarily due to the launch of Veklury (remdesivir).

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead 4Q Revenues: $7.4 billion (+26%) 4Q Earnings: $1.5 billion (-43%) YTD Revenues: $24.7 billion (+10%) YTD Earnings: $123 million (earnings were $5.4 billion FY19) Comments: Revenue growth for the quarter and full year was primarily due to the launch of Veklury (remdesivir) in 2020. Product sales excluding Veklury for the quarter and full year 2020 decreased 7% and 3%, respectively, due to the continued effects of COVID-19 on Gilead’s HIV and hepatitis C virus franchises, as well as th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters